JP2001503741A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503741A5
JP2001503741A5 JP1998516967A JP51696798A JP2001503741A5 JP 2001503741 A5 JP2001503741 A5 JP 2001503741A5 JP 1998516967 A JP1998516967 A JP 1998516967A JP 51696798 A JP51696798 A JP 51696798A JP 2001503741 A5 JP2001503741 A5 JP 2001503741A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998516967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503741A (ja
Filing date
Publication date
Priority claimed from US08/725,968 external-priority patent/US5849719A/en
Application filed filed Critical
Publication of JP2001503741A publication Critical patent/JP2001503741A/ja
Publication of JP2001503741A5 publication Critical patent/JP2001503741A5/ja
Ceased legal-status Critical Current

Links

JP51696798A 1996-10-04 1997-10-06 アレルギー性肺疾患を治療するための方法 Ceased JP2001503741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/725,968 1996-10-04
US08/725,968 US5849719A (en) 1993-08-26 1996-10-04 Method for treating allergic lung disease
PCT/US1997/018084 WO1998014210A1 (en) 1996-10-04 1997-10-06 Method for treating allergic lung disease

Publications (2)

Publication Number Publication Date
JP2001503741A JP2001503741A (ja) 2001-03-21
JP2001503741A5 true JP2001503741A5 (https=) 2005-05-12

Family

ID=24916669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51696798A Ceased JP2001503741A (ja) 1996-10-04 1997-10-06 アレルギー性肺疾患を治療するための方法

Country Status (8)

Country Link
US (4) US5849719A (https=)
EP (1) EP0935470B1 (https=)
JP (1) JP2001503741A (https=)
AT (1) ATE293992T1 (https=)
AU (1) AU740600B2 (https=)
CA (1) CA2267675A1 (https=)
DE (1) DE69733145T2 (https=)
WO (1) WO1998014210A1 (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US20030109469A1 (en) * 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
CA2244946C (en) * 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
IL133708A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
MXPA00006072A (es) * 1997-12-19 2003-07-14 Harvard College Metodos y composiciones para inhibir el crecimiento de celulas tumorales.
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US7244714B1 (en) 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1104456A1 (en) * 1998-08-10 2001-06-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
ATE326239T1 (de) * 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
JP3707303B2 (ja) * 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
ATE419869T1 (de) 1999-08-19 2009-01-15 Dynavax Tech Corp Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2001227889A1 (en) * 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2001094419A2 (en) * 2000-06-07 2001-12-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to induce the th1 immune response
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
KR100881923B1 (ko) * 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20040248837A1 (en) * 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
JP5102959B2 (ja) * 2002-12-23 2012-12-19 ダイナバックス テクノロジーズ コーポレイション 免疫刺激配列オリゴヌクレオチド及びその使用方法
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
NZ577196A (en) * 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
CN101163494A (zh) 2005-02-23 2008-04-16 Uab研究基金会 烷基糖苷增强的接种
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
ATE439135T1 (de) 2005-07-01 2009-08-15 Index Pharmaceuticals Ab Modulierung der reaktion auf steroide
AU2006266503B2 (en) 2005-07-01 2011-12-08 Index Pharmaceuticals Ab Immunostimulatory method
AU2006306805A1 (en) * 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
EP2612867A1 (en) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
US9717657B2 (en) 2012-10-24 2017-08-01 Amy Dukoff Composition and method of using medicament for endodontic irrigation, stem cell preparations and tissue regeneration
JP2022537318A (ja) 2019-06-17 2022-08-25 バイオマルク ファーマシューティカルズ リミテッド ぶどう膜炎の処置におけるペプチド及びその使用の方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228795A (en) * 1977-03-08 1980-10-21 Babington Robert S Apparatus for producing finely divided liquid spray
CA2489769A1 (en) * 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
EP0714308A4 (en) * 1993-08-26 1998-07-29 Univ California METHOD, COMPOSITIONS AND DEVICES FOR THE ADMINISTRATION OF NAKED POLYNUCLEOTIDS, WHICH ENCODE FOR BIOLOGICALLY ACTIVE PEPTIDES
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052962A1 (en) 1997-05-19 1998-11-26 Merck & Co., Inc. Oligonucleotide adjuvant
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
JP4663113B2 (ja) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
CA2398756A1 (en) * 2000-01-31 2001-08-02 Eyal Raz Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof

Similar Documents

Publication Publication Date Title
JP2000502280A5 (https=)
JP2001503384A5 (https=)
JP2000501771A5 (https=)
JP2000501599A5 (https=)
JP2000501018A5 (https=)
JP2000500076A5 (https=)
JP2001503741A5 (https=)
JP2000500055A5 (https=)
JP2000500026A5 (https=)
JP2000502472A5 (https=)
JP2000501825A5 (https=)
JP2000502425A5 (https=)
JP2000502485A5 (https=)
JP2001511768A5 (https=)
JP2000502568A5 (https=)
JP2000501774A5 (https=)
JP2000502570A5 (https=)
JP2000501876A5 (https=)
JP2001506363A5 (https=)
JP2000501744A5 (https=)
JP2000501229A5 (https=)
JP2000502316A5 (https=)
JP2002514126A5 (https=)
JP2000502714A5 (https=)
JP2000500184A5 (https=)